QQQ $ 607.08 $ -3.76 (-0.62 %)
DIA $ 468.03 $ -1.19 (-0.25 %)
SPY $ 669.19 $ -2.73 (-0.41 %)
TLT $ 91.95 $ -0.04 (-0.04 %)
GLD $ 371.42 $ -1.45 (-0.39 %)
$ 10.76
-- x --
-- x --
-- - --
$ 7.83 - $ 11.80
2,461,878
na
2.78B
$ 1.20
$ 983.39
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-03-2025 01-01-1970 10-K
2 11-04-2024 09-30-2024 10-Q
3 08-06-2024 06-30-2024 10-Q
4 05-09-2024 03-31-2024 10-Q
5 03-12-2024 12-31-2023 10-K
6 11-07-2023 09-30-2023 10-Q
7 08-08-2023 06-30-2023 10-Q
8 05-09-2023 03-31-2023 10-Q
9 03-10-2023 12-31-2022 10-K
10 11-10-2022 09-30-2022 10-Q
11 08-10-2022 06-30-2022 10-Q
12 05-13-2022 03-31-2022 10-Q
13 03-30-2022 12-31-2021 10-K
14 12-03-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Clearwater Will Deliver Industry's First Unified, Cloud-Native Front-to-Back Platform for Institutional InvestorsClearwater...

Core News & Articles

Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced tha...

 william-blair-downgrades-enfusion-to-market-perform

William Blair analyst Bhavan Suri downgrades Enfusion (NYSE:ENFN) from Outperform to Market Perform.

Core News & Articles

Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced the...

 piper-sandler-maintains-neutral-on-enfusion-raises-price-target-to-115

Piper Sandler analyst Sumeet Mody maintains Enfusion (NYSE:ENFN) with a Neutral and raises the price target from $10 to $11.5.

 stifel-maintains-buy-on-enfusion-raises-price-target-to-13

Stifel analyst Parker Lane maintains Enfusion (NYSE:ENFN) with a Buy and raises the price target from $11 to $13.

 enfusion-narrows-fy2024-sales-guidance-from-20000m-21000m-to-20200m-20500m--vs-est-2048m

Enfusion (NYSE:ENFN) narrows FY2024 sales outlook from $200.00 million-210.00 million to $202.00 million-205.00 million.

 enfusion-q3-adj-005-misses-006-estimate-sales-5117m-miss-5217m-estimate

Enfusion (NYSE:ENFN) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16....

 enfusion-is-interviewing-investment-banks-to-explore-options-including-a-potential-sale-sources-say

-Reuters

 enfusion-q2-2024-adj-eps-005-misses-006-estimate-sales-49455m-miss-50046m-estimate

Enfusion (NYSE:ENFN) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16....

 enfusion-q1-2024-adj-eps-006-beats-004-estimate-sales-48052m-beat-47616m-estimate

Enfusion (NYSE:ENFN) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 50 pe...

 watching-enfusion-spruce-point-capital-management-issues-short-report-on-co-says-based-on-our-investigation-we-estimate-a-40-to-60-downside-risk

https://www.sprucepointcap.com/research/enfusion-inc After conducting a forensic review of Enfusion, a technology provider for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION